Lead Product Candidate
Specialty High-Titer Immune Globulin
Our lead product candidate (RI-002) targets the unmet needs of immune deficient patients. We are currently dosing patients in our fully enrolled pivotal Phase III clinical trial in accordance with the protocol.
ADMA Biologics is a late stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. Our product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with infectious diseases.
ADMA also operates ADMA BioCenters, an FDA-licensed, GHA-certified source plasma collection facility which provides a portion of blood plasma for the manufacture of the our lead product candidate RI-002.
FDA Approved Plasma Procurement
Plasma Collection Center
Our FDA-licensed, GHA-certified source plasma collection facility provides safe, self-sourced raw material plasma for our lead product candidate as well as serves the needs of our customers with a reliable supply of source plasma. Click here for more information. Learn how to become a life-saving plasma donor today!
- Jun 16, 2014 ADMA Biologics Forms Scientific Advisory Board with Expertise in Immune Deficiencies, Infectious Diseases and Transplantation
- Jun 13, 2014 ADMA Biologics to Present at 9th Annual JMP Securities Healthcare Conference on June 24
- May 12, 2014 ADMA Biologics Reports First Quarter 2014 Financial and Operational Results